AKLIEF

This brand name is authorized in United States. It is also authorized in Canada, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Malta, Netherlands, Poland, Romania, Spain.

Active ingredients

The drug AKLIEF contains one active pharmaceutical ingredient (API):

1	Trifarotene UNII 0J8RN2W0HK - TRIFAROTENE
	Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. Trifarotene cream is used for the topical treatment of acne vulgaris.
	Read more about Trifarotene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AKLIEF Cream	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D10AD06		D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AD Retinoids for topical use in acne
Discover more medicines within D10AD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02494175
EE	Ravimiamet	1848843, 1848865, 1848876, 1848887
ES	Centro de información online de medicamentos de la AEMPS	85017
FI	Lääkealan turvallisuus- ja kehittämiskeskus	515832
FR	Base de données publique des médicaments	63631908
HK	Department of Health Drug Office	67256
HR	Agencija za lijekove i medicinske proizvode	HR-H-888420870
MT	Medicines Authority	MA117/01501
NL	Z-Index G-Standaard, PRK	203785
PL	Rejestru Produktów Leczniczych	100412716
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68352001, W68352002, W68352003, W68352004
US	FDA, National Drug Code	0299-5935